drugset / Trial / NCT01125631

Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

NCT01125631 ↗

Phase 1 Completed 8 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to examine the safety and tolerability of a multiple dose of PF-04360365 administered over approximately 10 minutes in Japanese patients with mild-to-moderate Alzheimer's disease and to characterize the pharmacokinetics of PF-04360365 following administration of multiple doses in Japanese patients with mild-to-moderate Alzheimer's disease.

Timeline

Start
2010-05
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponezumab Monoclonal antibody 8.5 mg/kg Intravenous

Indications